Table 2 Cardiovascular outcomes (after 90 days of ADT initiation) among patients on GnRH antagonists and agonists by pre-existing cardiovascular disease.
All | Pre-existing CVDa | No pre-existing CVD | |||||||
|---|---|---|---|---|---|---|---|---|---|
GnRH antagonist N = 499 | GnRH agonist N = 15,127 | GnRH antagonist N = 167 | GnRH agonist N = 3348 | GnRH antagonist N = 332 | GnRH agonist N = 11,779 | ||||
n (%) | n (%) | P value | n (%) | n (%) | P value | n (%) | n (%) | P value | |
Receiving hyperlipidemia treatment | 125 (25.1) | 5183 (34.3) | <0.0001 | 61 (36.5) | 1589 (47.5) | 0.0057 | 64 (19.3) | 3594 (30.5) | <0.0001 |
Receiving cardiac therapy | 123 (24.6) | 4960 (32.8) | <0.0001 | 56 (33.5) | 1381 (41.3) | 0.0478 | 67 (20.2) | 3579 (30.4) | <0.0001 |
IHD, stroke or CHF | 18 (3.6) | 1758 (11.6) | <0.0001 | 3 (1.8) | 410 (12.3) | <0.0001 | 15 (4.5) | 1348 (11.4) | <0.0001 |
Vital status | 0.3939 | 0.6542 | 0.6231 | ||||||
Alive | 377 (75.6) | 11,229 (74.2) | 130 (77.8) | 2570 (76.8) | 247 (74.3) | 8659 (73.5) | |||
CV-related death | 7 (1.4) | 348 (2.3) | 2 (1.2) | 76 (2.3) | 5 (1.5) | 272 (2.3) | |||
Other cause death | 115 (23.0) | 3550 (23.5) | 35 (21.0) | 702 (21.0) | 80 (24.1) | 2848 (24.2) | |||
